WOK · Work Medical Technology Group Ltd - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · WOK
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q3 '24 | Q3 '23 | Q3 '22 | Q3 '21 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q3 '24 | Q3 '23 | Q3 '22 | Q3 '21 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.09M | $2.00M | $6.56M | $1.60M | $731.2K | $873.1K |
| Accounts Receivable | $615.8K | $876.7K | $1.65M | $3.33M | - | - |
| Inventory | $2.46M | $2.98M | $3.18M | $4.62M | - | - |
| Accounts Payable | $1.72M | $1.47M | $1.50M | $3.96M | - | - |
| Current Assets | $20.46M | $21.58M | $20.83M | $22.15M | - | - |
| Total Assets | $33.16M | $34.71M | $36.25M | $29.96M | - | - |
| Current Liabilities | $11.97M | $18.98M | $20.18M | $18.92M | - | - |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $11.99M | $19.00M | $20.18M | $18.97M | - | - |
| Stockholders' Equity | $18.34M | $12.95M | $13.19M | $9.88M | $11.19M | $11.39M |
| Retained Earnings | $4.96M | $6.09M | $6.08M | $9.58M | - | - |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q3 '24 | Q3 '23 | Q3 '22 | Q3 '21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q3 '24 | Q3 '23 | Q3 '22 | Q3 '21 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | - | - | - | - | - | - |
| Return on equity | - | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.71 | 1.14 | 1.03 | 1.17 | - | - |
| Quick ratio | 1.50 | 0.98 | 0.87 | 0.93 | - | - |
| Cash ratio | 0.34 | 0.11 | 0.32 | 0.08 | - | - |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.81 | 2.68 | 2.75 | 3.03 | - | - |
| Liabilities / Assets | 0.36 | 0.55 | 0.56 | 0.63 | - | - |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 39.1% | - | 33.5% | -11.7% | -1.8% | - |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing WORK Medical Technology Group LTD against the 5 most active filers in the same SIC group.